A 62-year-old man presents with type 2 diabetes, hypertension, and albuminuria. His seated BP is 162/104 mm Hg. What's an ideal blood pressure target for this patient? A. 140/90 mm Hg B. 130/80 mm Hg C. 120/70 mm Hg D. 150/80 mm HG Did you get it right? Follow the link to find out!

Should prediabetes be considered a pre-existing condition? Follow the link to share your opinion!

Sanofi’s My Dose Coach app joins other insulin dosing apps recently cleared by the FDA, and new dosing tools from Novo Nordisk/Glooko. Sanofi’s My Dose Coach, a new, under-the-radar mobile app for adjusting basal insulin doses for those on injections, received FDA clearance in late March. A healthcare provider prescribes and sets up the My Dose Coach mobile app so that it can suggest optimized basal insulin injection doses for people with diabetes. The app will use fasting blood glucose and hypoglycemia data and recommend changes in doses if readings are too high or too low. Release date is unknown.

We all make the assumption that insulin resistance comes from eating too much glucose. However, for many patients, this resistance occurs because they release too much insulin. This can be environmentally related or it can be blamed on heredity. Regardless of the cause, this hyperinsulinemia can result in long-lasting effects …

23-year-old female, type 1 diabetes since 5 years of age. A1C elevated to 8.9% after usually having A1Cs in the 6-7 range. Came to see me at the end of our workday after wearing LibrePro (Blinded CGM) to go over her food/insulin/glucose/activity/etc. patterns. First thing she said to me was that she had a Dexcom but hasn't worn it because battery in transmitter was out for the past 6 months. She told me she really hasn't been checking her glucose on a regular basis at all.

In part 6 of this Exclusive Interview, understanding how a parent or caregiver can monitor an adolescent who is using the system.

In this week's Homerun Slides, the effects of hyperinsulinism.

Glucose phosphorylation as a therapeutic target for diabetes: Early experiments using genetic overexpression of glucokinase in liver of rodent models showed promise for the protection against hyperglycemia during diabetes, spawning the development of glucokinase activators. These drugs interact with allosteric sites of glucokinase, thus promoting a conformation that exposes the catalytic domain and potentiates the activity of the enzyme.

The first line therapy for type 2 diabetes has long been metformin, and nowadays we are using it for patents who have prediabetes; it is also used “unofficially” by a lot of Weight Loss clinics. A lot of patients who are on metformin progress to insulin, and for many years …

Could diabetes cause increased rates of dementia?